Forian Inc (FORA)

In the past six months, Forian's stock price has been impacted by several events. Forian announced its third-quarter 2025 financial results, reporting a revenue increase and improved adjusted EBITDA. Roth Capital downgraded Forian to Neutral from Buy. The company announced its second-quarter 2025 financial results. Forian received an unsolicited take-private proposal from a group led by its CEO, Max Wygod. The company announced its first-quarter 2025 financial results. Forian announced a partnership with Databricks to deliver access to its Chartis product through Databricks Marketplace. The acquisition of Kyber Data Science has significantly impacted Forian's performance and outlook, driving revenue growth and expanding analytical capabilities into financial markets.

Forian's management expects to have seasonality in their results. The company's information contracts often provide for continuing information deliverables over multi-year periods, contributing to a predictable recurring revenue stream. Demand for integrated healthcare data assets and analytics is generally growing as clients seek solutions for complex questions about treatment patterns, patient outcomes, and market dynamics.

Forian, Inc. is a publicly traded healthtech firm specializing in data science-driven information and analytics solutions within the Healthcare sector, specifically in Health Information Services and Health Care Technology. Forian provides data management and analytics solutions to optimize operational, clinical, and financial performance for clients in life science, healthcare, and financial services. Its major products and solutions include data management and data science technologies, commercial analytics, real-world evidence solutions, market access solutions, Chartis, and Kyber Data Science, which specializes in advanced healthcare data analytics and machine learning solutions. Previously, Forian also had a cannabis business (BioTrack), which was divested.

Forian, Inc. is headquartered in Newtown, Pennsylvania, United States.

Forian aims to build a reliable, leading-edge, and scalable brand in the healthcare information space. The company's name is derived from the Greek word "pliroforía," meaning information or intelligence, connoting clarity, strength, and a forward-thinking vision in the analytics space. The company emphasizes its commitment to leveraging data to improve health outcomes and business value, and has seen increased brand awareness in the past.

Forian, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Insider stakeholders control 55.34% of Forian's total share count. Adam H. Dublin is the largest individual shareholder, owning 20.50% of the company. Other major owners include Wygod Family Dynasty Trust Max, Edward Francis Spaniel Jr., Martin J. Wygod, Max C. Wygod, Oracle Investment Management Inc, Staley Capital Advisers Inc, and Vanguard Group Inc.